NASDAQ:ARDX - Ardelyx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.80 +0.05 (+0.87 %)
(As of 05/20/2018 09:55 AM ET)
Previous Close$5.80
Today's Range$5.70 - $5.90
52-Week Range$4.05 - $8.65
Volume151,605 shs
Average Volume248,879 shs
Market Capitalization$276.10 million
P/E Ratio-4.26
Dividend YieldN/A
Beta0.8

About Ardelyx (NASDAQ:ARDX)

Ardelyx logoArdelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Debt-to-Equity RatioN/A
Current Ratio10.28
Quick Ratio10.28

Price-To-Earnings

Trailing P/E Ratio-4.26
Forward P/E Ratio-3.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$42 million
Price / Sales6.57
Cash FlowN/A
Price / CashN/A
Book Value$2.71 per share
Price / Book2.14

Profitability

EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-39.53%
Return on Assets-35.10%

Miscellaneous

Employees75
Outstanding Shares47,600,000

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx (NASDAQ:ARDX) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.10. The biopharmaceutical company earned $2.32 million during the quarter. View Ardelyx's Earnings History.

What price target have analysts set for ARDX?

6 brokers have issued 1 year price objectives for Ardelyx's stock. Their forecasts range from $12.00 to $17.00. On average, they anticipate Ardelyx's share price to reach $13.6667 in the next year. View Analyst Ratings for Ardelyx.

What are Wall Street analysts saying about Ardelyx stock?

Here are some recent quotes from research analysts about Ardelyx stock:
  • 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (3/20/2018)
  • 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)

Who are some of Ardelyx's key competitors?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
  • Dr. Reginald Seeto, COO & Exec. VP (Age 46)
  • Dr. Paul Korner, Chief Medical Officer & Exec. VP (Age 52)
  • Mr. Mark E. Kaufmann MBA, CFO & Treasurer (Age 50)
  • Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)

Has Ardelyx been receiving favorable news coverage?

Media stories about ARDX stock have been trending positive on Sunday, according to Accern. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.45 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 44.88 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.47%), Opaleye Management Inc. (2.39%), Dimensional Fund Advisors LP (1.95%), JPMorgan Chase & Co. (1.72%), Millennium Management LLC (0.89%) and DAFNA Capital Management LLC (0.52%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeremy S Caldwell, Nea 15 Gp, Llc and Reginald Seeto. View Institutional Ownership Trends for Ardelyx.

Which major investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. Company insiders that have sold Ardelyx company stock in the last year include Forest Baskett and Reginald Seeto. View Insider Buying and Selling for Ardelyx.

Which major investors are buying Ardelyx stock?

ARDX stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Opaleye Management Inc., Foresite Capital Management III LLC, Millennium Management LLC, Foresite Capital Management II LLC, Sofinnova Ventures Inc, A.R.T. Advisors LLC and BlackRock Inc.. View Insider Buying and Selling for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $5.80.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $276.10 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (ARDX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ardelyx (NASDAQ:ARDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Ardelyx in the last 12 months. Their average twelve-month price target is $13.6667, suggesting that the stock has a possible upside of 135.63%. The high price target for ARDX is $17.00 and the low price target for ARDX is $12.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.6667$13.6667$13.6667$16.00
Price Target Upside: 135.63% upside155.45% upside140.61% upside153.97% upside

Ardelyx (NASDAQ:ARDX) Consensus Price Target History

Price Target History for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Leerink SwannReiterated RatingOutperform ➝ Outperform$13.00MediumView Rating Details
3/17/2018Cantor FitzgeraldSet Price TargetBuy$12.00MediumView Rating Details
3/15/2018WedbushReiterated RatingOutperformMediumView Rating Details
11/29/2017CitigroupBoost Price TargetBuy ➝ Buy$16.00 ➝ $17.00LowView Rating Details
11/22/2017Ladenburg ThalmannLower Price TargetBuy ➝ Buy$19.00 ➝ $16.00N/AView Rating Details
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 ➝ $12.00HighView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Ardelyx (NASDAQ:ARDX) Earnings History and Estimates Chart

Earnings by Quarter for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.44)($0.20)($0.32)
Q2 20182($0.48)($0.43)($0.46)
Q3 20182($0.51)($0.45)($0.48)
Q4 20182($0.47)($0.47)($0.47)

Ardelyx (NASDAQ ARDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.4580)($0.36)$2.32 millionViewN/AView Earnings Details
3/14/2018Q4 2017($0.39)$0.21$6.00 million$42.00 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.54)($0.44)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.63)($0.54)ViewListenView Earnings Details
5/5/2017Q1 2017($0.6520)($0.59)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.6570)($0.66)ViewN/AView Earnings Details
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.0150)($0.19)$9.65 million$5.88 millionViewN/AView Earnings Details
2/25/2015Q4 2014($0.06)($0.21)$8.15 million$6.34 millionViewListenView Earnings Details
8/7/2014Q2 2014$1.83$0.44$8.10 million$9.14 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ardelyx (NASDAQ:ARDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ardelyx (NASDAQ ARDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 74.41%
Insider Trading History for Ardelyx (NASDAQ:ARDX)
Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ ARDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/24/2017Reginald SeetoCOOSell10,008$5.20$52,041.60View SEC Filing  
8/30/2017Forest BaskettMajor ShareholderSell485$4.95$2,400.75View SEC Filing  
4/18/2017David P. RosenbaumInsiderSell2,051$11.98$24,570.98View SEC Filing  
3/3/2017Jeremy S. CaldwellEVPSell1,026$14.14$14,507.64View SEC Filing  
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.0022,144View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.001,440View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.0047,420View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.0047,420View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.0025,880View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.4025,880View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.0047,420View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.651,518View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.8625,880View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ardelyx (NASDAQ ARDX) News Headlines

Source:
DateHeadline
Ardelyx (ARDX) Rating Increased to Hold at BidaskClubArdelyx (ARDX) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - May 17 at 4:59 PM
Ardelyx Looks Cheap But Not Without RiskArdelyx Looks Cheap But Not Without Risk
seekingalpha.com - May 17 at 9:20 AM
Ardelyx (ARDX) Expected to Announce Earnings of -$0.46 Per ShareArdelyx (ARDX) Expected to Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - May 14 at 3:19 PM
Ardelyx Expected to Earn Q2 2018 Earnings of ($0.43) Per Share (ARDX)Ardelyx Expected to Earn Q2 2018 Earnings of ($0.43) Per Share (ARDX)
www.americanbankingnews.com - May 14 at 2:50 AM
Wedbush Weighs in on Ardelyxs FY2022 Earnings (ARDX)Wedbush Weighs in on Ardelyx's FY2022 Earnings (ARDX)
www.americanbankingnews.com - May 11 at 11:59 AM
Ardelyx (ARDX) Given Average Rating of "Hold" by AnalystsArdelyx (ARDX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 10 at 5:37 AM
Ardelyx (ARDX) Releases  Earnings Results, Beats Estimates By $0.10 EPSArdelyx (ARDX) Releases Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - May 9 at 3:17 PM
Ardelyx: 1Q Earnings SnapshotArdelyx: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:14 AM
Ardelyx Reports First Quarter 2018 Financial Results and Recent Business HighlightsArdelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
finance.yahoo.com - May 8 at 4:44 PM
Zacks: Analysts Expect Ardelyx (ARDX) to Announce -$0.42 EPSZacks: Analysts Expect Ardelyx (ARDX) to Announce -$0.42 EPS
www.americanbankingnews.com - April 27 at 1:26 AM
BidaskClub Upgrades Ardelyx (ARDX) to "Hold"BidaskClub Upgrades Ardelyx (ARDX) to "Hold"
www.americanbankingnews.com - April 19 at 11:03 AM
Ardelyx (ARDX) Forecasted to Earn Q1 2018 Earnings of ($0.44) Per ShareArdelyx (ARDX) Forecasted to Earn Q1 2018 Earnings of ($0.44) Per Share
www.americanbankingnews.com - April 18 at 7:58 AM
FY2021 Earnings Estimate for Ardelyx (ARDX) Issued By Leerink SwannFY2021 Earnings Estimate for Ardelyx (ARDX) Issued By Leerink Swann
www.americanbankingnews.com - April 17 at 7:07 AM
Ardelyx (ARDX) Given Average Recommendation of "Hold" by AnalystsArdelyx (ARDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 5:45 AM
Comparing Syndax Pharmaceuticals (SNDX) and Ardelyx (ARDX)Comparing Syndax Pharmaceuticals (SNDX) and Ardelyx (ARDX)
www.americanbankingnews.com - April 11 at 3:32 AM
Ardelyx (ARDX) Given a $12.00 Price Target by Cantor Fitzgerald AnalystsArdelyx (ARDX) Given a $12.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 11 at 12:43 AM
-$0.40 EPS Expected for Ardelyx (ARDX) This Quarter-$0.40 EPS Expected for Ardelyx (ARDX) This Quarter
www.americanbankingnews.com - April 10 at 3:10 AM
Ardelyx (ARDX) Downgraded by ValuEngine to Strong SellArdelyx (ARDX) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 25 at 8:45 PM
 Analysts Expect Ardelyx Inc (ARDX) to Announce -$0.40 Earnings Per Share Analysts Expect Ardelyx Inc (ARDX) to Announce -$0.40 Earnings Per Share
www.americanbankingnews.com - March 24 at 3:21 AM
Cantor Fitzgerald Research Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX)Cantor Fitzgerald Research Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX)
www.americanbankingnews.com - March 23 at 10:56 AM
Ardelyx Inc to Post Q1 2018 Earnings of ($0.40) Per Share, Leerink Swann Forecasts (ARDX)Ardelyx Inc to Post Q1 2018 Earnings of ($0.40) Per Share, Leerink Swann Forecasts (ARDX)
www.americanbankingnews.com - March 21 at 7:20 AM
Ardelyx Inc (ARDX) Receives Average Recommendation of "Hold" from AnalystsArdelyx Inc (ARDX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 5:36 AM
Ardelyx (ARDX) Downgraded by Zacks Investment Research to SellArdelyx (ARDX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 20 at 5:56 PM
Ardelyx (ARDX) Now Covered by Analysts at Leerink SwannArdelyx (ARDX) Now Covered by Analysts at Leerink Swann
www.americanbankingnews.com - March 19 at 10:46 AM
Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in CanadaArdelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
finance.yahoo.com - March 19 at 10:00 AM
Ardelyx Inc (ARDX) Forecasted to Post FY2021 Earnings of $0.70 Per ShareArdelyx Inc (ARDX) Forecasted to Post FY2021 Earnings of $0.70 Per Share
www.americanbankingnews.com - March 19 at 9:48 AM
Ardelyxs (ARDX) Outperform Rating Reaffirmed at WedbushArdelyx's (ARDX) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 18 at 5:38 PM
BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21
www.reuters.com - March 16 at 10:03 AM
Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of DirectorsArdelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
finance.yahoo.com - March 14 at 4:41 PM
Ardelyx posts 4Q profitArdelyx posts 4Q profit
finance.yahoo.com - March 14 at 4:41 PM
Ardelyx Inc (ARDX) Receives Consensus Rating of "Hold" from AnalystsArdelyx Inc (ARDX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 5:36 AM
Ardelyx (ARDX) Downgraded by BidaskClub to "Sell"Ardelyx (ARDX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 18 at 3:32 PM
Cantor Fitzgerald Reiterates "$12.00" Price Target for Ardelyx (ARDX)Cantor Fitzgerald Reiterates "$12.00" Price Target for Ardelyx (ARDX)
www.americanbankingnews.com - February 12 at 1:32 PM
Ardelyx (ARDX) Reports Departure its Chief Scientific Officer - StreetInsider.comArdelyx (ARDX) Reports Departure its Chief Scientific Officer - StreetInsider.com
www.streetinsider.com - February 12 at 6:37 AM
Ardelyx Announces Departure of Chief Scientific OfficerArdelyx Announces Departure of Chief Scientific Officer
finance.yahoo.com - February 12 at 6:37 AM
Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceArdelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:24 PM
Ardelyx (ARDX) Downgraded by BidaskClubArdelyx (ARDX) Downgraded by BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Ardelyx (ARDX) Cut to Hold at Zacks Investment ResearchArdelyx (ARDX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - February 2 at 5:36 PM
Ardelyx (ARDX) Stock Rating Upgraded by Zacks Investment ResearchArdelyx (ARDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 30 at 5:56 PM
Ardelyx Inc (ARDX) Given Average Recommendation of "Buy" by BrokeragesArdelyx Inc (ARDX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 30 at 8:18 AM
Ardelyx (ARDX) Stock Rating Upgraded by BidaskClubArdelyx (ARDX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 27 at 4:28 PM
Ardelyx (ARDX) Downgraded by Zacks Investment Research to HoldArdelyx (ARDX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 23 at 6:44 PM
Ardelyx (ARDX) Stock Rating Lowered by BidaskClubArdelyx (ARDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 21 at 4:58 PM
Stock Review for Biotechs Investors -- Ardelyx, Verastem, and ... - PR Newswire (press release)Stock Review for Biotech's Investors -- Ardelyx, Verastem, and ... - PR Newswire (press release)
www.prnewswire.com - January 12 at 11:08 AM
BRIEF-Ardelyx Says Co Had About $134 Million In CashBRIEF-Ardelyx Says Co Had About $134 Million In Cash
www.reuters.com - January 8 at 8:56 AM
Ardelyx Inc (ARDX) Receives Consensus Rating of "Buy" from BrokeragesArdelyx Inc (ARDX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 8:28 AM
Can The Uptrend Continue for Ardelyx (ARDX)?Can The Uptrend Continue for Ardelyx (ARDX)?
finance.yahoo.com - January 4 at 11:03 AM
Ardelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA ... - StreetInsider.comArdelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA ... - StreetInsider.com
www.streetinsider.com - January 3 at 3:50 PM
BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-CBRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C
www.reuters.com - January 3 at 10:38 AM
Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?
finance.yahoo.com - January 3 at 10:38 AM

SEC Filings

Ardelyx (NASDAQ:ARDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ardelyx (NASDAQ:ARDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ardelyx (NASDAQ ARDX) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.